breast cancer

graphic of a larger shark chomping up a smaller one
Biotech

Novartis pays $2B for breast cancer program as rivals circle

Novartis is paying Synnovation $2 billion upfront for an asset that could defend its breast cancer franchise from challengers including Eli Lilly.
Nick Paul Taylor Mar 20, 2026 5:19am
gold arrow pointing upward forward

Pfizer's hotly tipped breast cancer prospect records phase 2 win

Mar 17, 2026 8:40am
breast cancer mammogram

AI could spot heart disease in breast cancer mammograms

Mar 9, 2026 2:25pm
failure crash no fail rocket cancelled end

Roche's oral SERD flunks 1st-line breast cancer phase 3

Mar 9, 2026 6:40am
FDA conference hall

FDA to end 9-month adcomm hiatus with review of AZ cancer drugs

Mar 6, 2026 11:16am
Make a delay and accumulation of outstanding tasks Full stop

Accent halts DHX9 inhibitor trial over adverse events

Feb 26, 2026 5:01am